ID

36684

Beskrivning

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR); ODM derived from: https://clinicaltrials.gov/show/NCT02293733

Länk

https://clinicaltrials.gov/show/NCT02293733

Nyckelord

Versioner (1)
  1. 2019-06-01 2019-06-01 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

1 juni 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

Engelsk

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

1 Formulär  
Eligibility Criteria
Beskrivning

Eligibility Criteria

inclusion criteria:
Beskrivning

Inclusion criteria

Datatyp

boolean

Alias
UMLS CUI [1]
C1512693
nsclc patients with activating mutations of egfr
Beskrivning

Non-Small Cell Lung Carcinoma | EGFR Activating Mutation

Datatyp

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2]
C2984891
first-line treatment with a tki monotherapy
Beskrivning

First line treatment Tyrosine kinase inhibitor

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1268567
measurable lesion according to recist 1.1
Beskrivning

Measurable lesion

Datatyp

boolean

Alias
UMLS CUI [1]
C1513041
age> 18 years
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
secondary or acquired resistance of egfr tkis according to the jackman criteria
Beskrivning

Resistance Secondary EGFR TKI | Resistance Acquired EGFR TKI

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0013203
UMLS CUI [1,2]
C0175668
UMLS CUI [1,3]
C1443775
UMLS CUI [2,1]
C0013203
UMLS CUI [2,2]
C0439661
UMLS CUI [2,3]
C1443775
patients for whom it was started a tki treatment in first line from january 2010 until june 2012 (patients who received 1 chemotherapy cycle could be included).
Beskrivning

First line treatment Tyrosine kinase inhibitor | Chemotherapy cycle Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1268567
UMLS CUI [2,1]
C1302181
UMLS CUI [2,2]
C1265611
exclusion criteria:
Beskrivning

Exclusion Criteria

Datatyp

boolean

Alias
UMLS CUI [1]
C0680251
patients with small cell carcinoma
Beskrivning

Carcinoma, Small Cell

Datatyp

boolean

Alias
UMLS CUI [1]
C0262584
patients without egfr mutation
Beskrivning

EGFR mutation Absent

Datatyp

boolean

Alias
UMLS CUI [1,1]
C3266992
UMLS CUI [1,2]
C0332197
patients not treated with egfr tki in first line treatment
Beskrivning

First line treatment EGFR Tyrosine kinase inhibitor Absent

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1443775
UMLS CUI [1,3]
C0332197
not measurable lesion to recist 1.1
Beskrivning

Measurable lesion Absent

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0332197
Tillbaka till toppen

Similar models

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Inclusion criteria
Item
inclusion criteria:
boolean
C1512693 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | EGFR Activating Mutation
Item
nsclc patients with activating mutations of egfr
boolean
C0007131 (UMLS CUI [1])
C2984891 (UMLS CUI [2])
First line treatment Tyrosine kinase inhibitor
Item
first-line treatment with a tki monotherapy
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
Measurable lesion
Item
measurable lesion according to recist 1.1
boolean
C1513041 (UMLS CUI [1])
Age
Item
age> 18 years
boolean
C0001779 (UMLS CUI [1])
Resistance Secondary EGFR TKI | Resistance Acquired EGFR TKI
Item
secondary or acquired resistance of egfr tkis according to the jackman criteria
boolean
C0013203 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C1443775 (UMLS CUI [1,3])
C0013203 (UMLS CUI [2,1])
C0439661 (UMLS CUI [2,2])
C1443775 (UMLS CUI [2,3])
First line treatment Tyrosine kinase inhibitor | Chemotherapy cycle Quantity
Item
patients for whom it was started a tki treatment in first line from january 2010 until june 2012 (patients who received 1 chemotherapy cycle could be included).
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Exclusion Criteria
Item
exclusion criteria:
boolean
C0680251 (UMLS CUI [1])
Carcinoma, Small Cell
Item
patients with small cell carcinoma
boolean
C0262584 (UMLS CUI [1])
EGFR mutation Absent
Item
patients without egfr mutation
boolean
C3266992 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
First line treatment EGFR Tyrosine kinase inhibitor Absent
Item
patients not treated with egfr tki in first line treatment
boolean
C1708063 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Measurable lesion Absent
Item
not measurable lesion to recist 1.1
boolean
C1513041 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial